Loading stock data…
MGNX
$3.13+0.05 (+1.62%)
Market ClosedLast close May 1
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MacroGenics, Inc. in the Healthcare sector is trading at $3.13. The stock is currently 19% below its 52-week high of $3.88, remaining 60.5% above its 200-day moving average. Technical signals show neutral RSI of 33 and bearish MACD signal, explaining why MGNX maintains its current momentum and trend strength. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 33) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.13
Potential Upside
5%
Whystock Fair Value$3.29
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$205.62M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-86.94%
Volume
Today's trading volume
457,050
Recent News
SNY's Tzield Gets FDA Nod for Kids, Sarclisa SC BLA Faces Delay
Sanofi wins FDA nod to expand Tzield's use to younger patients, while Sarclisa SC review faces delay with a new decision date set for July 2026.
B. Riley Sees Upside in MacroGenics, Inc. (MGNX) Following Gilead-Driven Sector Activity
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. MacroGenics, Inc. is one of the best biotech stocks. TheFly reported on April 10 that B. Riley raised its rating on MGNX to Buy from Neutral and assigned a $9 price target. The firm highlighted the company’s positioning in the […]
April 2026's Most Promising Penny Stocks
The U.S. market has experienced a notable climb, rising 1.2% in the last week and 33% over the past year, with earnings projected to grow significantly in the coming years. In such a robust market climate, identifying stocks with strong financial foundations is crucial for investors seeking value beyond established names. Penny stocks, often representing smaller or newer companies, remain an intriguing investment area despite their somewhat outdated label; they can offer surprising...
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of +47.31% and +71.24%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics: Q4 Earnings Snapshot
ROCKVILLE, Md. AP) — MacroGenics Inc. MGNX) on Monday reported a loss of $14.2 million in its fourth quarter.